In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Poor outcomes in pulmonary arterial hypertension as a member of RNF213-associated vascular diseases

Session Basic mechanisms of pulmonary disease

Speaker Takahiro Hiraide

Congress : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Moderated Posters
  • FP Number : P6009

Authors : T Hiraide (Tokyo,JP), M Kataoka (Tokyo,JP), H Suzuki (Tokyo,JP), Y Aimi (Tokyo,JP), T Chiba (Tokyo,JP), S Isobe (Tokyo,JP), Y Katsumata (Tokyo,JP), S Goto (Tokyo,JP), K Kanekura (Tokyo,JP), T Satoh (Tokyo,JP), M Sano (Tokyo,JP), S Gamou (Tokyo,JP), K Kosaki (Tokyo,JP), K Fukuda (Tokyo,JP)

Authors:
T Hiraide1 , M Kataoka1 , H Suzuki2 , Y Aimi3 , T Chiba4 , S Isobe1 , Y Katsumata1 , S Goto1 , K Kanekura5 , T Satoh3 , M Sano1 , S Gamou1 , K Kosaki2 , K Fukuda1 , 1Keio University School of Medicine, Cardiology - Tokyo - Japan , 2Keio University School of Medicine, Center for Medical Genetics - Tokyo - Japan , 3Kyorin University School of Medicine, Division of Cardiology, Second Department of Internal Medicine - Tokyo - Japan , 4Kyorin University School of Medicine, Department of Pathology - Tokyo - Japan , 5Tokyo Medical University, Department of Molecular Pathology - Tokyo - Japan ,

Citation:

Background: A variant of c.14429G>A (p.Arg4810Lys, rs112735431) in the ring finger protein 213 gene (RNF213; NM_001256071.2) has been recently identified as a risk allele for pulmonary arterial hypertension (PAH), suggesting that PAH can be added as a new member of RNF213-associated vascular diseases including Moyamoya disease and peripheral pulmonary stenosis.

Purpose: Our aim was to identify the clinical features and outcomes of PAH patients with RNF213 p.Arg4810Lys variant.

Methods: Whole-exome sequencing was performed in 139 idiopathic (or possibly heritable) PAH patients. Hemodynamics and prognosis were evaluated in the patients with RNF213 p.Arg4810Lys variant and the patients with bone morphogenic protein receptor type 2 (BMPR2) mutations.

Results: The RNF213 p.Arg4810Lys variant was identified in a heterozygous state in 11 patients (7.9%). Time-course changes in hemodynamics after combination therapy in the patients with the RNF213 p.Arg4810Lys variant were significantly poorer compared with those in BMPR2 mutation carriers (n=36) (comparison of changes in mean pulmonary arterial pressure, P=0.007). The event-free rate of death or lung transplantation was significantly poorer in RNF213 p.Arg4810Lys variant carriers than in BMPR2 mutation carriers (5-year event-free rate since the introduction of prostaglandin I2 infusion, 0% vs. 93%, P<0.001) (Figure).

Conclusions: PAH patients with the RNF213 p.Arg4810Lys variant were associated with a poor reactivity to vasodilator drugs and poor clinical outcomes even in the recent era. Earlier consideration of lung transplantation might be required for RNF213 p.Arg4810Lys variant carriers developing PAH. Documentation of the RNF213 p.Arg4810Lys variant, as well as already known pathogenic genes, can provide clinically relevant information for therapeutic strategies, leading to a personalized approach for the treatment of PAH.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are